Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell of lymphatic vessel | 10 studies | 29% ± 11% | |
B cell | 8 studies | 19% ± 2% | |
endothelial cell | 5 studies | 26% ± 6% | |
memory B cell | 4 studies | 16% ± 1% | |
CD4-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
non-classical monocyte | 3 studies | 25% ± 6% | |
capillary endothelial cell | 3 studies | 28% ± 12% | |
immature B cell | 3 studies | 24% ± 7% | |
precursor B cell | 3 studies | 30% ± 6% | |
pro-B cell | 3 studies | 29% ± 7% | |
naive B cell | 3 studies | 20% ± 4% |
Insufficient scRNA-seq data for expression of MAP4K2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 2845.67 | 653 / 653 | 100% | 11.04 | 605 / 605 |
uterus | 100% | 1787.57 | 170 / 170 | 100% | 12.03 | 458 / 459 |
brain | 100% | 3282.64 | 2635 / 2642 | 100% | 11.93 | 705 / 705 |
lung | 100% | 3992.95 | 578 / 578 | 100% | 13.37 | 1151 / 1155 |
prostate | 100% | 1860.13 | 244 / 245 | 100% | 9.04 | 501 / 502 |
breast | 100% | 1714.49 | 457 / 459 | 100% | 12.05 | 1114 / 1118 |
bladder | 100% | 1842.52 | 21 / 21 | 99% | 12.36 | 500 / 504 |
intestine | 100% | 2248.18 | 966 / 966 | 99% | 8.86 | 521 / 527 |
stomach | 100% | 1740.62 | 359 / 359 | 99% | 9.45 | 282 / 286 |
kidney | 100% | 1661.20 | 89 / 89 | 98% | 7.50 | 887 / 901 |
ovary | 100% | 1326.48 | 180 / 180 | 98% | 10.15 | 423 / 430 |
esophagus | 98% | 1562.51 | 1421 / 1445 | 100% | 12.07 | 183 / 183 |
skin | 97% | 1075.70 | 1760 / 1809 | 100% | 12.71 | 471 / 472 |
adrenal gland | 100% | 1578.36 | 257 / 258 | 97% | 10.21 | 222 / 230 |
pancreas | 96% | 839.77 | 315 / 328 | 98% | 9.66 | 174 / 178 |
liver | 63% | 383.98 | 142 / 226 | 91% | 5.38 | 370 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 8.49 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 33.00 | 29 / 29 |
spleen | 100% | 6990.83 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 11.72 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.63 | 1 / 1 |
adipose | 99% | 1569.18 | 1197 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 4078.71 | 922 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 1293.28 | 1320 / 1335 | 0% | 0 | 0 / 0 |
heart | 96% | 965.44 | 829 / 861 | 0% | 0 | 0 / 0 |
muscle | 36% | 208.68 | 291 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043507 | Biological process | positive regulation of JUN kinase activity |
GO_0006955 | Biological process | immune response |
GO_0007254 | Biological process | JNK cascade |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0006468 | Biological process | protein phosphorylation |
GO_0006903 | Biological process | vesicle targeting |
GO_0045087 | Biological process | innate immune response |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0016323 | Cellular component | basolateral plasma membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0031435 | Molecular function | mitogen-activated protein kinase kinase kinase binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0008349 | Molecular function | MAP kinase kinase kinase kinase activity |
Gene name | MAP4K2 |
Protein name | Mitogen-activated protein kinase kinase kinase kinase 2 Mitogen-activated protein kinase kinase kinase kinase 2 (EC 2.7.11.1) (B lymphocyte serine/threonine-protein kinase) (Germinal center kinase) (GC kinase) (MAPK/ERK kinase kinase kinase 2) (MEK kinase kinase 2) (MEKKK 2) (Rab8-interacting protein) non-specific serine/threonine protein kinase (EC 2.7.11.1) |
Synonyms | GCK RAB8IP |
Description | FUNCTION: Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion. . |
Accessions | ENST00000439069.5 ENST00000433890.5 ENST00000424945.5 ENST00000435926.5 ENST00000444560.1 H7C208 ENST00000294066.7 [Q12851-1] Q12851 F2Z2B3 ENST00000377350.7 [Q12851-2] C9JCU6 F8WCP4 |